Loading
A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.
Elicio's amphiphile peptides (7 mKRAS antigens) plus CpG adjuvant, engineered to drain to lymph nodes. Phase 1 AMPLIFY-201 induced mKRAS-specific T cells in most patients with ctDNA reductions. Randomised phase 2 AMPLIFY-7P (adjuvant PDAC, results June 2026) did not meet its primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses reported ~14% absolute DFS benefit during active treatment. Elicio is refining a phase 3 strategy around R0-resected patients.
Albumin-binding lipid tails carry mutant-KRAS peptides to lymph nodes for dendritic cell presentation. Connects to KRAS.
1.ELI-002 7P slips into a pocket on KRAS.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ELI-002 7P" OR ABSTRACT:"ELI-002 7P") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELI-002 7P, not a curated reading list.
Shares Pancreatic cancer: the failed and stopped programmes and why, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares AMPLIFY-7P, Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Metastatic pancreatic ductal adenocarcinoma.
Shares Off-the-shelf cancer vaccines, KRAS, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, KRAS.
Shares Off-the-shelf cancer vaccines, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, MRD / molecular residual disease testing.
Shares Pancreatic cancer: the failed and stopped programmes and why, Off-the-shelf cancer vaccines, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma.
Shares Off-the-shelf cancer vaccines, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, The undruggable drivers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.